-
Alarm bells!
Time of Update: 2022-08-11
Click to enter the exhibition pageRecently, there have been news of a large number of pharmacies being fined for publishing false advertisements, circumventing normal sales channels, selling prescription drugs without prescriptions, and not issuing sales vouchers, etc.
-
The Science and Technology Biopharmaceutical Index was released, and 8 pharmaceutical companies in Jiangsu were on the list
Time of Update: 2022-08-11
According to the data, in 2021, Nuotai Bio will achieve an operating income of 644 million yuan, a year-on-year increase of 13.
According to the data, in 2021, Nuotai Bio will achieve an operating income of 644 million yuan, a year-on-year increase of 13.
-
Blockbuster small molecule drugs officially announced the new crown treatment potential from 1 to 2 to take the new blue ocean
Time of Update: 2022-08-11
In this race against the new crown, another innovative pharmaceutical company, Ascentage Pharma (6855. HK), came to an end, bringing fresh blood and a turning point to this protracted battle . Because
-
Baiji, Ascentage, Gracell, etc. to Announce Latest Clinical Data of Blockbuster Drugs at ASCO 2022
Time of Update: 2022-08-11
Updated clinical data from a multicenter, investigator-initiated trial (IIT) in refractory multiple myeloma (RRMM) On May 27, Gracell announced that it will present its B-cell maturation antigen (BCMA)/CD19 dual-target CAR-T product candidate GC012F in the form of an oral presentation at the American Society of Clinical Oncology 2022 Annual Meeting (ASCO 2022).
-
The State Pharmacopoeia Commission began to solicit proposals for the 2023 national drug standard improvement project
Time of Update: 2022-08-11
affixed with the official seal, personal signature is required) and the electronic version of the materials will be fed back to our commission All relevant units are requested to focus on the compilation of the 2025 edition of the "Chinese Pharmacopoeia", put forward proposals for project establishment, and fill in the "2023 National Drug Standard Improvement Project Proposal Form" (see attachment), and submit the paper materials (units need to be required) before June 20, 2022.
-
On the same day, two first generic drugs were approved for marketing!
Time of Update: 2022-08-11
In recent years, the first generic drug in China has become one of the key areas of competition for pharmaceutical companies to expand their territory .
In recent years, the first generic drug in China has become one of the key areas of competition for pharmaceutical companies to expand their territory .
-
Focus on anti-tumor and nervous system drugs, what are the FDA-approved drugs in the first quarter?
Time of Update: 2022-08-11
Table 1: FDA-approved BLA biologics in the first quarter of 2022 Data source: China Pharmaceutical Industry Information Center, Pharma ONE intelligent drug big data analysis platform Approved original chemical drug Among the 35 approved NDA drugs, 6 Type1-new molecular entity new drugs are worthy of attention, including 3 anti-tumor and immunomodulatory agents: Vonjo (pairitinib) is an inhibitor of JAK2, IRAK1 and CSF1R.
-
101 new items added!
Time of Update: 2022-08-11
. Article 31 [General requirements for the evaluation of traditional Chinese medicines] The drug regulatory department of the State Council shall meet the major strategic needs of the country and the needs of people's life and health, follow the laws of traditional Chinese medicine research and development, scientifically and rationally set the technical requirements for traditional Chinese medicine evaluation, establish traditional Chinese medicine theory, traditional Chinese medicine human use A review evidence system combining experience and clinical trials .
-
Domestic pharmaceutical companies and multinational pharmaceutical companies are racing on two opposite tracks
Time of Update: 2022-08-11
Don't you see, large multinational pharmaceutical companies, mainly Pfizer and Sanofi, have "abandoned their soldiers to protect their leaders", throwing away product pipelines such as consumption, health care, and generic drugs; domestic pharmaceutical companies, on the contrary, have branched into medical beauty, CXO, and diversified products.
-
Announcement of the first batch of national drug standards for traditional Chinese medicine formula granules
Time of Update: 2022-08-11
. In order to ensure the scientificity, rationality and applicability of the standards, opinions from all walks of life are solicited on the publicity of the national drug standards for the above-mentioned traditional Chinese medicine formula granules (see the annex for details) .
-
The over 20 billion contrast agent market welcomes a new member!
Time of Update: 2022-08-11
Click to enter the exhibition pageRecently, Puli Pharmaceutical announced that the company recently received the marketing authorization for iopamidol injection issued by the Dutch Drug Evaluation Committee .
-
The net profit of 5 pharmaceutical companies in the first quarter of 2022 entered the "1 billion club" for the first time
Time of Update: 2022-08-11
Click to enter the exhibition pageRecently, while listed companies have disclosed their 2021 annual reports, their performance in the first quarter of 2022 has also been gradually announced .
-
In-depth analysis of the procurement volume of the two major alliances, centralized procurement forces the rational admission of traditional Chinese medicine imitation
Time of Update: 2022-08-11
New entrants cut prices for the market It can be seen from the centralized procurement rules of the Hubei Regional Alliance and the Guangdong Regional Alliance for the centralized procurement of Chinese patent medicines that if the generic varieties of traditional Chinese medicines want to compete for the market, it is difficult to obtain the procurement volume of medical institutions at the beginning .
-
CDE Announcement on Issuing the "General Format and Guidelines for Writing Instructions for Chemical Drugs and Biological Products" (No. 28 of 2022)
Time of Update: 2022-08-11
Notice of the Center for Drug Evaluation of the State Food and Drug Administration on Issuing the "General Format and Writing Guidelines for the Instructions of Chemical Drugs and Biological Products
-
The enthusiasm for ADC drug development is high, and another pharmaceutical company ADC innovative drug has been granted priority review qualification by the FDA
Time of Update: 2022-08-11
Huadong Medicine stated that Mirvetuximab Soravtansine is a FRα-targeted ADC drug, and it is also a key product under development in the company's innovative tumor drug pipeline .
-
Mirati Announces Latest Results of KRAS Inhibitor for the Treatment of Non-Small Cell Lung Cancer
Time of Update: 2022-08-11
Mirati Therapeutics announced positive results from a Phase 2 clinical trial of its KRAS G12C inhibitor adagrasib in patients with previously treated non-small cell lung cancer harboring a KRAS G12C mutation .
-
In the past 5 trading days, more than 130 companies have obtained institutional research, and 2 pharmaceutical companies have attracted much attention
Time of Update: 2022-08-11
In addition, according to the company's 2022 first quarter report, the main income was 180 million yuan, a year-on-year increase of 30.
In addition, according to the company's 2022 first quarter report, the main income was 180 million yuan, a year-on-year increase of 30.
-
Reflections on the change management of pharmaceutical excipients and pharmaceutical packaging materials under the related review policy
Time of Update: 2022-08-11
Summary OBJECTIVE: To provide reference for the implementation of the change management system for pharmaceutical excipients and pharmaceutical packaging materials under China's related review and ap
-
The number of innovative drugs approved has reached a new high, and domestic independent research and development has entered the harvest period
Time of Update: 2022-08-11
Driven by multiple advantages such as policies, capital, and talents, the pace of domestic innovative drug listings has been accelerating With the continuous improvement of the innovation strength of local pharmaceutical companies, China's contribution to global pharmaceutical innovation is also increasing.
-
The per capita annual salary of pharmaceutical companies in 2021 will exceed 160,000 yuan, and 4 companies will increase their salary by more than 100%
Time of Update: 2022-08-11
Flush iFinD data shows that the per capita annual salary of 442 listed pharmaceutical companies will reach 168,300 yuan in 2021, an increase of 12.
Flush iFinD data shows that the per capita annual salary of 442 listed pharmaceutical companies will reach 168,300 yuan in 2021, an increase of 12.
